Repligen Corporation RGEN R3KPHARMA

Q: What is the current share price of Repligen Corporation (RGEN)?

As of 2026-09-19 21:16 PDT, Repligen Corporation (RGEN) trades at $168.53 on NasdaqGS. Its 52-week range is $102.87 to $182.03.

Q: What is the market capitalisation of RGEN?

Repligen Corporation (RGEN) has a market capitalisation of $9.51B on NasdaqGS.

Q: What is the P/E ratio of RGEN?

RGEN trades at a trailing price-to-earnings (P/E) ratio of 230.86. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.73.

Q: What is the return on equity (ROE) of RGEN?

RGEN has a return on equity (ROE) of 1.99%. Its return on capital employed (ROCE) is 1.48%.

Q: Is RGEN a good stock to buy?

This page provides a data-driven analysis of Repligen Corporation (RGEN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Instruments & Supplies · United States

https://www.repligen.com

Company Profile ↓

$168.53

+32.54% 1Y

Mkt Cap$9.51B

P/E230.86

P/B4.73

52W High$182.03

52W Low$102.87

Book Value$37.43

EPS (TTM)$0.73

Company Overview

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 26.8% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.33.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $738.26M (+16.4% YoY); net profit $48.89M.
Trailing 12 Months Year-on-year growth — revenue +11.9%, earnings -65.9%.
5-Year Trend Long-term compounding — revenue CAGR 26.8%, profit CAGR -4.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	26.80%
1 Year:	11.90%

Compounded Profit Growth

5 Years:	-3.99%
1 Year:	-65.90%

Stock Price Performance

1 Year:	+32.54%
6 Months:	+31.78%
3 Months:	+34.47%
1 Month:	+2.82%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 83% of range

$102.87 $182.03

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)51.38 · Neutral

Price Performance

1M+2.82%

3M+34.47%

6M+31.78%

1Y+32.54%

Valuation vs Sector

P/E of 230.86 is above the sector median of 24.83 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 26.8% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading at a high P/E of 230.9.
Earnings shrank at -4.0% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

230.86

Industry PE

24.83

Forward P/E

63.60

PEG Ratio

1.72

Book Value

$37.43

Price to Book

4.73

P/S

12.72

EV/EBITDA

68.45

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

26.80%

Profit 5Y

-3.99%

Revenue (YoY)

11.90%

Earnings (YoY)

-65.90%

Profitability & Returns

ROCE

1.48%

ROE

1.99%

ROA

1.40%

Profit Margin

5.29%

Op Margin

9.31%

Gross Margin

53.84%

EPS (Latest Qtr)

$0.09

EPS (TTM)

$0.73

Balance Sheet & Liquidity

Debt/Equity

0.33

Quick Ratio

7.30

Current Ratio

9.05

Debt

$690.94M

Total Assets

$2.95B

Current Assets

$1.20B

Working Capital

$1.00B

Ownership

Promoter Holding

5.25%

Chg in Prom Hold

0.00%

FII / Inst Holding

120.04%

Chg in FII Hold

-0.04%

Financial Snapshot

Enterprise Value

$9.51B

Total Revenue (TTM)

$785.10M

EBITDA

$144.10M

Free Cash Flow

$113.42M

Operating Cash Flow

$134.86M

Shares Outstanding

56.44M

Gross Margin

53.84%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	RGEN Repligen Corporation R3KPHARMA	168.53	230.86	$9.51B	0.00%	1.48%	1.99%	26.80%	-3.99%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	19.81M	21.45M	25.09M	29.17M	24.68M	25.60M	30.59M	32.45M	36.58M	41.61M	44.83M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	182.37M	188.81M	197.91M	194.25M	204.13M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	89.37M	88.29M	94.08M	85.97M	94.09M
Gross Profit	-	-	-	-	-	-	16.60M	18.52M	16.59M	22.48M	25.16M	26.64M	27.35M	28.35M	33.79M	39.98M	38.02M	39.35M	44.11M	50.60M	54.43M	60.48M	-	-	-	-	-	-	-	-	-	-	-	-	-	93.00M	100.52M	103.83M	108.28M	110.04M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	84.88M	87.84M	87.48M	90.99M	91.03M
Operating Income	3.69M	1.43M	3.46M	5.86M	3.75M	2.90M	5.68M	5.47M	-406.00K	3.26M	5.98M	4.27M	7.89M	-	11.17M	11.05M	7.96M	-	11.91M	19.54M	20.96M	-	36.38M	48.24M	45.19M	60.00M	63.17M	52.66M	31.26M	19.40M	4.69M	3.75M	5.47M	-7.83M	-	8.12M	12.68M	16.35M	17.29M	19.00M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48.34M	46.94M	49.20M	31.89M	43.59M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.35M	5.41M	5.50M	5.58M	5.66M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18.21M	17.11M	19.11M	1.77M	14.15M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.35M	2.20M	5.83M	-6.56M	9.14M
Net Income	2.54M	265.00K	1.62M	3.87M	1.16M	5.03M	3.07M	8.44M	4.67M	12.18M	3.45M	2.74M	4.79M	5.64M	8.05M	8.10M	1.66M	3.60M	9.81M	15.86M	14.55M	19.70M	29.45M	36.23M	33.50M	46.96M	49.86M	40.41M	28.83M	20.06M	16.92M	3.30M	5.71M	-654.00K	-	14.87M	14.91M	13.29M	8.33M	5.01M
Diluted EPS	0.08	0.01	0.05	0.11	0.03	0.15	0.09	0.24	0.11	0.27	0.08	0.06	0.10	0.12	0.17	0.17	0.03	0.07	0.18	0.30	0.27	0.36	0.52	0.64	0.58	0.81	0.88	0.71	0.51	0.35	0.30	0.06	0.10	-0.01	-	0.26	0.26	0.23	0.15	0.09
R&D Expense	1.49M	1.43M	1.54M	1.89M	1.89M	2.04M	1.74M	1.86M	2.00M	3.07M	3.29M	5.78M	3.60M	-	3.62M	5.23M	5.43M	-	4.70M	4.34M	4.42M	-	7.61M	8.39M	9.15M	12.15M	10.44M	10.23M	12.15M	9.71M	10.58M	11.24M	10.57M	9.71M	12.11M	13.97M	14.18M	-	14.46M	14.42M

Profit & Loss (Annual)

Figures in USD.

Metric	Mar 2010	Mar 2011	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	20.97M	27.29M	-	62.27M	68.17M	63.55M	83.54M	104.54M	141.24M	194.03M	270.25M	366.26M	670.53M	801.54M	632.36M	634.44M	738.26M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	345.83M	353.92M	359.79M	352.01M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	455.71M	278.44M	274.64M	386.25M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	259.76M	261.31M	306.57M	344.69M
Operating Income	-5.77M	-374.07K	-	11.08M	22.87M	10.69M	13.76M	15.97M	14.01M	25.99M	36.08M	69.82M	167.25M	195.94M	17.13M	-31.92M	41.56M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	277.31M	145.32M	80.26M	180.85M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	1.16M	2.50M	20.73M	21.51M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	219.14M	56.71M	-27.04M	62.38M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	33.18M	21.11M	-1.52M	13.49M
Net Income	-4.06M	-43.51K	-1.61M	14.16M	16.09M	8.17M	9.35M	11.68M	28.35M	16.62M	21.41M	59.93M	128.29M	185.96M	35.60M	-25.51M	48.89M
Diluted EPS	-0.13	0.00	-	0.45	0.50	0.25	0.28	0.34	0.72	0.37	0.44	1.11	2.24	3.24	0.74	-0.46	0.86
R&D Expense	14.16M	12.53M	-	10.49M	7.34M	5.61M	5.74M	7.36M	8.67M	15.82M	19.45M	20.18M	34.27M	43.94M	42.72M	43.20M	54.18M

Balance Sheet (Annual)

Figures in USD.

Metric	Mar 2009	Mar 2010	Dec 2010	Mar 2011	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	72.29M	76.06M	97.01M	118.64M	128.29M	146.24M	288.91M	743.52M	774.62M	1.40B	1.90B	-	2.53B	2.83B	2.83B	2.95B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	998.12M	1.11B	1.07B	1.14B
Cash & Equivalents	5.04M	12.53M	9.79M	14.20M	11.17M	29.21M	39.83M	35.36M	54.09M	122.23M	173.76M	193.82M	528.39M	717.29M	-	523.46M	751.32M	757.36M	566.02M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	238.28M	202.32M	142.96M	170.46M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	116.25M	124.16M	134.12M	158.59M
Total Liabilities	-	-	-	-	-	-	-	-	-	-	151.97M	159.05M	340.35M	373.74M	-	620.90M	866.34M	856.95M	843.57M
Current Liabilities	-	-	-	4.62M	7.46M	10.75M	11.30M	10.68M	18.78M	21.07M	25.21M	129.84M	48.31M	318.96M	-	404.20M	164.94M	126.79M	135.83M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	510.14M	525.57M	542.21M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	422.96M	711.80M	686.25M	689.95M
Total Equity	69.12M	66.12M	67.09M	67.09M	65.99M	84.12M	84.12M	111.73M	122.75M	168.76M	591.55M	615.57M	1.06B	1.53B	-	1.91B	1.96B	1.97B	2.11B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55.56M	55.77M	56.09M	56.33M

Cash Flows (Annual)

Figures in USD.

Metric	Mar 2010	Mar 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-2.45M	3.23M	13.44M	25.93M	-	-	7.52M	17.45M	32.77M	67.22M	62.62M	-	172.08M	113.92M	175.39M	117.42M
Investing Cash Flow	9.92M	-1.50M	2.84M	-17.91M	-	-	-49.19M	-98.70M	-14.04M	-205.31M	-201.38M	-	-233.24M	-123.28M	-86.38M	-298.47M
Financing Cash Flow	11.59K	-50.28K	1.16M	2.52M	-	-	112.11M	129.94M	3.41M	484.87M	305.92M	-	-13.34M	248.96M	-82.90M	-15.21M
Capital Expenditure	-597.35K	-524.67K	-1.26M	-4.63M	-5.60M	-2.63M	-4.33M	-5.45M	-10.63M	-18.50M	-22.45M	-	-133.35M	-38.99M	-32.91M	-25.73M
Free Cash Flow	-3.05M	2.71M	12.18M	21.29M	-	-	3.20M	12.00M	22.14M	48.71M	40.17M	-	38.74M	74.93M	142.49M	91.69M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-74.49M	239.60M	6.11M	-196.26M
Share Buybacks	-	-	-	-	-	-	-	-	-	-	-	0	0	14.39M	0	0

Ratios (Annual)

Figures in %.

Metric	Mar 2010	Mar 2011	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	56.9%	44.0%	43.3%	52.3%
Operating Margin %	-27.5%	-1.4%	-	17.8%	33.6%	16.8%	16.5%	15.3%	9.9%	13.4%	13.4%	19.1%	24.9%	24.4%	2.7%	-5.0%	5.6%
Net Margin %	-19.4%	-0.2%	-	22.7%	23.6%	12.9%	11.2%	11.2%	20.1%	8.6%	7.9%	16.4%	19.1%	23.2%	5.6%	-4.0%	6.6%
ROE %	-6.1%	-0.1%	-2.4%	16.8%	19.1%	7.3%	7.6%	6.9%	4.8%	2.7%	2.0%	3.9%	-	9.7%	1.8%	-1.3%	2.3%
ROCE %	-	-0.6%	-	12.8%	21.3%	9.1%	10.8%	6.0%	1.9%	4.0%	2.7%	4.4%	-	9.2%	0.6%	-1.2%	1.5%

Shareholding Pattern

Insiders

5.25%

Institutions

120.04%

Public Float

126.68%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.54%	5.38M	$952.54M
2	FMR, LLC	5.89%	3.33M	$588.46M
3	United Capital Financial Advisors, LLC	4.94%	2.79M	$493.64M
4	Vanguard Capital Management LLC	4.27%	2.41M	$426.51M
5	Vanguard Portfolio Management LLC	4.10%	2.31M	$409.12M
6	Maverick Capital Ltd.	3.52%	1.98M	$351.05M
7	State Street Corporation	3.19%	1.80M	$318.50M
8	Price (T.Rowe) Associates Inc	3.10%	1.75M	$309.96M
9	Massachusetts Financial Services Co.	2.87%	1.62M	$286.03M
10	Wasatch Advisors LP	2.82%	1.59M	$281.30M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RGEN

Google News Fri, 04 Sep 2026

Repligen (RGEN) Stock Looks Near Fair Value After Recent Rebound - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOVDhEejNQOUM4MFZuSFdfUUJiVm5HOG1MMnpaN1ZIWVJnUUxjWU54RTJRSEV0LVFmMlE3aW5BNXRoZGp2X0padGxZSUhxSmxpTWtLU3ZwbkFkT050OHlDSDM4d2NnZFVnRkt0am1VU2ZGcmRjNk9laThUTUlkS0FSXzhtRmJHc2RGTFJFOV…

Google News ue, 08 Sep 2026

[425] REPLIGEN CORP Business Combination Communication | RGEN SEC Filing - Form 425 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQWWdVNVNpalV2ODNVMnNyRzh3ekhvZ3YyX3dVTjRXUFE0cFI3Nm1ZbVNtcVAySUdNNW41ZHRSNVNlRUNtdGkteVNEMnhDUmxwUS0xOWFHQzlxUVFEQXdBR0x2Y3E5RTl4eDFuZURUV0Z5VFF4YzdqMk1ZNHdjLVUyVTlOSnoydUxXMURXbF…

Google News Sat, 05 Sep 2026

Repligen Corp (NASDAQ:RGEN) Combines Strong Growth with a Constructive Technical Setup - ChartMill

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxORlBqX2lHUmhESThvQllfcjVEcWRidDI0US15dVY4VzBuLUFOQl9TdjhYYjl6R1JPbjhwQXZZdHI3bHRCaGtoa3ZFdEpzbG1aTEt2MEZxQWVtVjNaVHFsLXVGeFM3LV9ZR3N1WlpVLVhTd3hmTm1xRVRVVlgwMmd6QXZ5bkhWZnQ3VzJnUj…

Google News Mon, 07 Sep 2026

Repligen Corporation (RGEN) Stock Analysis: Uncovering a Potential 11.99% Upside in Bioprocessing - directorstalkinterviews.com

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPWWE1bjRIc0l2aTlCcDhTR3hGa0lOakxnZGlmSHc3UFRqVGd6SFJrRVBFMFVkcEp2bUFYRmV6d2Y5ZHRuZFFyT0ktVkJTdG1aaXFWMHVWMnVoc2JJWkZIRXVIYWhHOS0tWXU0MG1yYUE4QkY5MHgtcEhaVnhkVkRTY1doUGRVV25nbzAyRD…

Google News ue, 21 Jul 2026

Why Repligen (RGEN) Stock Is Trading Lower Today - StockStory

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQNUhJcWszd0l3amV4OURYYnE2N2tfNFRpTzFYbjJnLThleVFWN0ZFWk1PdjFVYUI2NjhJQVh4bkRtRnVlUEh5aUlENVhidU4zZW9Eb0U0dlU3bUpJcGdkRVd3R21uWUUxcWI0SDVBZWtWQjhoa01JaVNnMWYyRkkzWFBKZmx1ajBvSl9nVG…

Google News ue, 08 Sep 2026

Repligen to acquire BioLife for $11.25 cash plus 0.1442 shares per BioLife share; HSR waiting period expired - tradingview.com

<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxPNEZ5RkhBR3Rzc0tkV205Si1WdGc0dUo4WVpEZkxDdUtHR0cwdnB0Z1d5VFE3d0JrWndsLXp5M2w5WEo3Ukg5TFN3eVJSOGtiUUh5WndZMUVCcFlRNXp5OXQ0Z3V4dDFhY2Jkd2YtWEZ5Mm5ZdzdNNnR3ZHd4VEhXNmRxZEQ4RWpwdDM3cT…

RGEN — Frequently Asked Questions

What is the current share price of Repligen Corporation (RGEN)?

As of 2026-09-19 21:16 PDT, Repligen Corporation (RGEN) trades at $168.53 on NasdaqGS. Its 52-week range is $102.87 to $182.03.

What is the market capitalisation of RGEN?

Repligen Corporation (RGEN) has a market capitalisation of $9.51B on NasdaqGS.

What is the P/E ratio of RGEN?

RGEN trades at a trailing price-to-earnings (P/E) ratio of 230.86. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.73.

What is the return on equity (ROE) of RGEN?

RGEN has a return on equity (ROE) of 1.99%. Its return on capital employed (ROCE) is 1.48%.

Is RGEN a good stock to buy?

This page provides a data-driven analysis of Repligen Corporation (RGEN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Repligen Corporation RGEN R3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Repligen (RGEN) Stock Looks Near Fair Value After Recent Rebound - finance.yahoo.com

[425] REPLIGEN CORP Business Combination Communication | RGEN SEC Filing - Form 425 - Stock Titan

Repligen Corp (NASDAQ:RGEN) Combines Strong Growth with a Constructive Technical Setup - ChartMill

Repligen Corporation (RGEN) Stock Analysis: Uncovering a Potential 11.99% Upside in Bioprocessing - directorstalkinterviews.com

Why Repligen (RGEN) Stock Is Trading Lower Today - StockStory

Repligen to acquire BioLife for $11.25 cash plus 0.1442 shares per BioLife share; HSR waiting period expired - tradingview.com

RGEN — Frequently Asked Questions

What is the current share price of Repligen Corporation (RGEN)?

What is the market capitalisation of RGEN?

What is the P/E ratio of RGEN?

What is the return on equity (ROE) of RGEN?

Is RGEN a good stock to buy?

Explore More